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Identity 
Other names: CREB1, CRE-BP1, CREB2, CREBP1, 
HB16, MGC111558, TREB7 
HGNC (Hugo): ATF2 
Location: 2q31.1 
Note 
ATF2 (2q31.1) is sometimes confused with CREB1 
(2q33.3), because an alias of ATF2 is CREB1, also 
because they are both CREB-related proteins, a family 
of transcription factors of the bZIP superfamily, whose 
members have the ability to heterodimerize with each 
other, and, finally, because CREB1, like ATF1 (but no
ATF2 so far), is a fusion partner of EWSR1 in various 
soft tissue tumors (clear cell sarcoma of the soft tissue,  
angiomatoid fibrous histiocytoma) harboring a 
t(2;22)(q33;q12) or a t(12;22)(q13;q12) respectively 
(review in Huret, 2010). 
DNA/RNA 
Description 
Gene size: 96 Kb. 
Transcription 
Initiation codon located in exon 3. Normal message is 
1518 nucleotides. Numerous splice variants (24 
according to Ensembl).  
A small isoform of ATF2, ATF2-small (ATF2-sm), 
with a calculated mass of 15 kDa, has no histone 
acetyltransferase (HAT) activity, but, still, has the 
ability to bind CRE-containing DNA.  
 
 
ATF2 gene structure based on data available in the Ensembl release 44. Upstream non-coding exons (green). Coding exons (pink), 
3' untranslated sequence (red). The size of the exons in nucleotides is indicated below each exon. Exon number is indicated within the 
exon. 
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ATF2-sm is only composed of the first two and last two
exons of ATF2. Within the body of the uterus, ATF2 
full length is expressed only in the lower segment, 
whereas there is a gradient of expression of the ATF2-
sm protein with the highest level in the upper segmnt. 
A significant number of genes are differentially 
regulated by the ATF2-fl and ATF2-sm transcription 




ATF2 is one of 16 members of the ATF and CREB 
group of bZIP transcription factors, components of the
activating protein 1 (AP-1). The canonical form of 
ATF2 is made of 505 amino acids, 54.537 kDa 
according to Swiss-Prot. ATF2 comprises from N-term 
to C-term a zinc finger (C2H2-type; DNA binding) 
(amino acids 25-49), a transactivation domain (aa 19-
106, Nagadoi et al., 1999), two proline-rich domain, 
(involved in protein-protein interaction) (Pro202, 207, 
210, 212, 214, 216, 222, 228, 231 and 243, 247, 251
256, 259, 261, 263, 267, 269), two glutamine-rich 
domains (involved in transcriptional trans-activation) 
(Gln268, 271, 284, 285 and 306, 313, 316, 317), a basic 
motif (amino acids 351-374), and a leucine zipper 
domain (amino acids 380-408, and a nuclear export 
signal), making a basic leucine zipper required for 
dimerization, and involved in CRE-binding (Kara et al.,
1990 and Swiss-Prot.). ATF2 contains two canonical 
nuclear localization signals (NLS) in its basic motif, 
and two nuclear export signal (NES) in its leucine 
zipper, one of which in N-term: (1)MKFKLHV(7) (Liu 
et al., 2006; Hsu and Hu, 2012). 
Expression 
Ubiquitously expressed. High expression in brain and
in regenerating liver (Takeda et al., 1991). 
Localisation 
Cytoplasmic and nuclear protein. The nuclear transport 
signals (NLS and NES) contribute to the shuttling of 
ATF2 between the cytoplasm and the nucleus. ATF2 
homodimers are localized in the cytoplasm, and prevent 
its nuclear import. Heterodimerization with JUN 
prevents nuclear export of ATF2. JUN-dependent 
nuclear localization of ATF2 occurs upon stimulating 
conditions (retinoic acid-induced differentiation and 
UV-induced cell death) (Liu et al., 2006). 
Phosphorylation of ATF2 on Thr52 by PRKCE 
(PKCE) promotes its nuclear retention and 
transcriptional activity (Lau et al., 2012). Stress- or 
damage-induced cytosolic localization of ATF2 could 
be associated with cell death (Lau and Ronai, 2012). 
When ATF2 translocates to the cytoplasm, it localizes 
at the mitochondrial outer membrane (Lau et al., 2012). 
Function 
- ATF2 is a transcription factor. ATF2 forms a 
homodimer or a heterodimer with JUN (Hai and 
Curran, 1991), or other proteins (see below). 
- Typically, it binds to the cAMP-responsive element 
(CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a 
sequence present in many cellular promoters (Hai et 
al.,1989). However, depending on the heterodimeric 
partner, ATF2 binds to different response elements o  
target genes. ATF2/JUN and ATF2/CREB1 bind the 
above noted concensus sequence. ATF2 is mainly a 
transcription activator, but it also may be a 
transcription repressor (reviews in Bhoumik and Ronai, 
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2008; Lopez-Bergami et al., 2010; Lau and Ronai, 
2012). 
Activation of ATF2 
ATF2 is activated by stress kinases, including JNK 
(MAPK8, MAPK9, MAPK10) and p38 (MAPK1, 
MAPK11, MAPK12, MAPK13, MAPK14) and is 
implicated in transcriptional regulation of immediate 
early genes regulating stress and DNA damage 
responses (Gupta et al., 1995; van Dam et al., 1995) 
and cell cycle control under normal growth 
conditions.(up-regulation of the CCNA2 (cyclin A) 
promoter at the G1/S boundary) (Nakamura et al., 
1995). In response to stimuli, ATF2 is phosphorylated 
on threonine 69 and/or 71 by JNK or by p38. 
Phosphorylation on Thr69 and Thr71 of ATF2 and its 
dimerization are required to activate ATF2 
transcription factor activity. Phosphorylation on Thr69 
occurs through the RALGDS-SRC-P38 pathway, and 
phosphorylation on Thr71 occurs through the RAS-
MEK-ERK pathway (MAPK1, MAPK3 (ERK1), 
MAPK11, MAPK12 and MAPK14) (Gupta et al., 
1995; Ouwens et al., 2002). 
The intrinsic histone acetylase activity of ATF2 
promotes its DNA binding ability (Abdel-Hafiz et al., 
1992; Kawasaki et al., 2000). 
Interaction of ATF2 with CREBBP (CREB-binding 
protein, also called p300/CBP) is dependent upon 
phosphorylation at Ser121 induced by PRKCA. ATF2 
and CREBBP cooperate in the activation of 
transcription (Kawasaki et al., 1998; Yamasaki et al., 
2009). 
VRK1 activates and stabilizes ATF2 through direct 
phosphorylation of Ser62 and Thr73 (Sevilla et al.,
2004). 
Down regulation of ATF2 
Among other down regulation mechanisms, ATF2 is 
down regulated, by MIR26B in response to ionizing 
radiation (Arora et al., 2011). 
Transcriptionally active dimers of ATF2 protein are 
regulated by ubiquitylation and proteosomal 
degradation (Fuchs et al., 1999); phosphorylation of 
ATF2 on Thr69 and Thr71 promotes its ubiquitylation 
and degradation (Firestein and Feuerstein, 1998). 
A cytoplasmic alternatively spliced isoform of ATF7, 
ATF7-4, is a cytoplasmic negative regulator of both 
ATF2 and ATF7. It impairs ATF2 and ATF7 
phosphorylation (ATF7-4 indeed sequesters the Thr53-
phosphorylating kinase in the cytoplasm, preventing 
Thr53 phosphorylation of ATF7) and transcriptional 
activity (Diring et al., 2011). 
The activity of ATF2 is repressed by an intramolecuar 
interaction between the N-terminal domain and the b-
ZIP domain (Li and Green, 1996). The N-terminal 
nuclear export signal (NES) of ATF2 negatively 
regulates ATF2 transcriptional activity (Hsu and Hu, 
2012). 
Dimerization of ATF2 
The basic leucine zipper (basic motif + leucine zipper, 
"b-ZIP") of ATF2 enables homo- or hetero-
dimerization. 
The main dimerization partners of ATF2 are the 
following: ATF2, BRCA1, CREB1, JDP2, JUN, JUNB, 
JUND, MAFA, NF1, NFYA, PDX1, POU2F1, TCF3 
(Lau and Ronai, 2012). 
ATF2 homodimers have a low transcriptional activity. 
MAPKAP1 (SIN1) binds to the b-ZIP region of ATF2, 
and also binds MAPK14, and is required for MAPK14-
induced phosphorylation of ATF2 in response to 
osmotic stress, and activates the transcription of 
apoptosis-related genes (Makino et al., 2006). 
In response to stress, ATF2 binds to POU2F1 (OCT1), 
NFI, and BRCA1 to activate transcription of GADD45. 
The b-Zip region of ATF2 is critical for binding to 
BRCA1. ATF2 also binds and activates SERPINB5 
(Maspin) (Maekawa et al., 2008). 
ATF2 also forms a heterodimer with JDP2, a repressor 
of AP-1. JDP2 inhibits the transactivation of JUN by 
ATF2 (Jin et al., 2002). 
ATF2 target genes 
Under genotoxic stress, a study showed that 269 genes 
were found to be bound by ATF2/JUN dimers. 
Immediate-early genes were a notable subset and 
included EGR family members, FOS family members, 
and JUN family members, but the largest group of 
genes belonged to the DNA repair machinery 
(Hayakawa et al., 2004, see below). 
Among the ATF2 target genes are : 
- Transcription factors, such as JUN, ATF3, DDIT3 
(CHOP), FOS, JUNB, 
- DNA damage proteins (see below), 
- Cell cycle regulators (CCNA2, CCND1), see below, 
- Regulators of apoptosis (see below and Hayakawa et 
al., 2004), 
- Growth factor receptors and cytokines such as 
PDGFRA (Maekawa et al., 1999), IL8 (Agelopoulos 
and Thanos, 2006), FASLG (Fas ligand), TNF 
(TNFalpha), TNFSF10 family (Herr et al., 2000; Faris 
et al., 1998), 
- Proteins related with invasion such as MMP2 (Hams 
and Kuttan, 2012) and PLAU (UPA): ATF2/JUN 
heterodimer binds to and activates PLAU (De Cesare et 
al., 1995), 
- Cell adhesion molecules, such as SELE, SELP, and 
VCAM1 (Reimold et al., 2001), 
- Proteins engaged in the response to endoplasmic 
reticulum (ER) stress. ATF2/CREB dimers bind the 
CRE-like element TGACGTGA of HSPA5 (Grp78) 
and activates it (Chen et al., 1997), 
- Genes encoding extracellular matrix components 
seem to constitute an important subset of ATF2/JUN-
target genes (van Dam and Castellazzi, 2001). 
- PTEN, a negative regulator of the PI3K/AKT 
signaling pathway, is positively regulated by ATF2 
(Qian et al., 2012). 
- ATF1 and ATF2 regulate TCRA and TCRB gene 
transcription. 
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Histones, Chromatin 
UV treatment or ATF2 phosphorylation increases its 
histone acetyltransferase (HAT) activity as well as its 
transcriptional activities. Lys296, Gly297 and Gly299, 
are essential both for histone acetyltransferase activity 
and for transactivation (Kawasaki et al., 2000). 
Binding of ATF2 to the histone acetyltransferase 
RUVBL2 (TIP49b) suppresses ATF2 transcriptional 
activity. RUVBL2's association with ATF2 is 
phosphorylation dependent and requires amino acids 
150 to 248 of ATF2 (Cho et al., 2001). 
ATF2 interacts with the acetyltransferase domains of 
CREBBP. ATF2 b-ZIP could serve as an 
acetyltransferase substrate for the acetyltransferase 
domains of CREBBP. ATF2 is acetylated on Lys357 
and Lys374 by CREBBP, which contributes to its 
transcriptional activity (Karanam et al., 2007). 
ATF2 and ATF4 are essential for the transcriptional 
activation of DDIT3 (CHOP) upon amino acid 
starvation. 
ATF2 is essential in the acetylation of histone H4 and 
H2B, and thereby may be involved in the modification 
of the chromatin structure. An ATF2-independent HAT 
activity is involved in the amino acid regulation of
ASNS transcription (Bruhat et al., 2007). 
The histone variant macroH2A recruitement into 
nucleosomes could confer an epigenetic mark for gene 
repression. The constitutive DNA binding of the 
ATF2/JUND heterodimer to the IL-8 enhancer recruits 
macroH2A-containing nucleosomes in B cells, thus 
inhibiting transcriptional activation (Agelopoulos and 
Thanos, 2006). 
Heat shock or osmotic stress induces phosphorylation 
of dATF2 (ATF2 in Drosophila), results in its release 
from heterochromatin, and heterochromatic disruption. 
dATF2 regulates heterochromatin formation. ATF2 
may be involved in the epigenetic silencing of target 
genes in euchromatin. The stress-induced ATF2-
dependent epigenetic change was maintained over 
generations, suggesting a mechanism by which the 
effects of stress can be inherited (Seong et al., 2011). 
DNA damage response 
Phosphorylation on Ser490 and Ser498 by ATM is 
required for the activation of ATF2 in DNA damage 
response. Phosphorylation of ATF2 results in the 
localisation of ATF2 in ionizing radiation induced foci 
(in cells exposed to ionizing radiation (IR), several 
proteins phosphorylated by ATM translocate and 
colocalize to common intranuclear sites. The resulting 
IR-induced nuclear foci (IRIF) accumulate at the sites 
of DNA damage). ATF2 expression contributes to the 
selective recruitment of MRE11A, RAD50, and NBN 
(NBS1) into IRIF. ATF2 is required for the IR-induced 
S phase checkpoint, and this function is independant of 
its transcriptional activity (Bhoumik et al., 2005). 
KAT5 (TIP60) is a histone acetyltransferase and 
chromatin-modifying protein involved in double strand 
breaks (DSB) repair, interacting with and acetylating 
ATM. ATF2 associates with KAT5 and RUVBL2. 
Under non-stressed conditions, ATF2 in cooperation 
with the ubiquitin ligase CUL3 promotes the 
degradation of KAT5 (Bhoumik et al., 2008a). 
Following genotoxic stress, 269 genes were found to be 
bound by ATF2/JUN dimers (see above), of which 
were 23 DNA repair or repair-associated genes 
(ERCC1, ERCC3, XPA, MSH2, MSH6, RAD50, 
RAD23B, MLH1, HIST1H2AC, PMS2, FOXN3 
(CHES1), LIG1, ERCC8 (CKN1), UNG, XRCC6 
(G22P1), TREX1, PNP, GTF2H1, ATM, FOXD1, 
DDX3X, DMC1, and the DNA repair-associated 
GADD45G), derived from several recognized DNA 
repair mechanisms (Hayakawa et al., 2004). 
Cell Cycle 
RB1 constrains cellular proliferation by activating the 
expression of the inhibitory growth factor TGFB2 
(TGF-beta 2) through ATF2 (Kim et al., 1992). 
CREB1 dimerizes with ATF2 to bind to the CCND1 
(cyclin D1) promoter, to increase CCD1 expression 
(Beier et al., 1999). 
JUND dimerizes with ATF2 to repress CDK4 
transcription, a protein necessary for the G1-to-S phase 
transition during the cell cycle, by binding to the 
proximal region of the CDK4-promoter, contributing to 
the inhibition of cell growth. The physical interactions 
of ATF2 with JUND implicates the b-ZIP domain of 
ATF2 (Xiao et al., 2010). 
Heterodimerization of JUND with ATF2 activates 
CCNA2 (cyclin A) promoter. CCNA2 is essential for 
the control at the G1/S and the G2/M transitions of the 
cell cycle.  
In contrast, ATF4 expression suppresses the promoter 
activation mediated by ATF2 (Shimizu et al., 1998). 
Apoptosis 
ATF2/CREB1 heterodimer binds to the CRE element 
of the BCL2 promoter (Ma et al., 2007). 
ATF2 induces BAK upregulation (Chen et al., 2010). 
MAP3K5 (ASK1) activates ATF2 and FADD-CASP8-
BID signalling, resulting in the translocation of BAX 
and BAK, and subsequently mitochondrial 
dysregulation (Hassan et al., 2009). 
ATF2/JUN heterodimers bind and activate CASP3, a 
key executor of neuronal apoptosis (Song et al., 2011). 
Following death receptor stimulation, there is 
phosphorylation and binding of ATF2/JUN to death-
inducing ligands promoters (FASLG, TNF, TNFSF10), 
which allows the spread of death signals (Herr et al., 
2000). Neuronal apoptosis requires the concomitant 
activation of ATF2/JUN and downregulation of FOS 
(Yuan et al., 2009). 
Many drugs are currently being tested for their ability 
to inhibit cell proliferation and induce apoptosis 
through various pathways, including ATF2 pathway. 
In the cytoplasm, ATF2 abrogates formation of 
complexes containing HK1 and VDAC1, deregulating 
mitochondrial outer-membrane permeability and 
initiating apoptosis. This function is negatively 
regulated phosphorylation of ATF2 by PRKCE, which 
dictates its nuclear localization (Lau et al., 2012). 
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Metabolic control and Insulin signalling 
ATF2 has been implicated in the regulation of proteins 
involved in metabolic control, including the control of 
the expression of UCP1, a protein involved in 
thermogenic response in brown adipose tissue (Cao et 
al., 2004) and phosphoenolpyruvate carboxykinase 
(PEPCK), a protein regulating gluconeogenesis 
(Cheong et al., 1998). 
Insulin activates ATF2 by phosphorylation of Thr69 
and Thr71 (Baan et al., 2006). 
Co-expression of ATF2, MAFA, PDX1, and TCF3 
results in a synergistic activation of the insulin 
promoter in endocrine cells of pancreatic islets. ATF2, 
MAFA, PDX1, and TCF3 form a multi-protein 
complex to facilitate insulin gene transcription (Han et 
al., 2011). 
ATF2 target genes in insulin signalling are ATF3, JUN, 
EGR1, DUSP1 (MKP1), and SREBF1. Deregulation of 
these genes is linked to the pathogenesis of insulin 
resistance, beta-cell dysfunction and vascular 
complications found in type 2 diabetes. Therefore, 
aberrant ATF2 activation under conditions of insulin 
resistance may contribute to the development of type 2 
diabetes (Baan et al., manuscript in preparation). 
Iron depletion  
Iron depletion induced by chelators increases the 
phosphorylation of JNK and MAPK14, as well as the 
phosphorylation of their downstream targets p53 and
ATF2 (Yu and Richardson, 2011). 
Mutations 
Note 
v-Rel-mediated transformation suggests opposing roles 
for ATF2 in oncogenesis. The increase in ATF2 
expression observed in v-Rel-transformed cells 
promotes oncogenesis. On the other hand, enhanced 
expression of ATF2 inhibits transformation by v-Rel. 
ATF2 can regulate signaling pathways in a cell type-
specific and/or context-dependent manner. Differences 
were found in the stage at which ATF2 regulated the 
RAS/RAF/MAPK signaling pathway in fibroblast 
(where it blocked the activation of RAF, 
MAP2K1/MAP2K2, MAPK1/MAPK3) and in the 
lymphoid DT40 B-cell line (where overexpression of 
ATF2 increased HRAS activity and phosphorylated 
RAF. ATF2 exhibits both oncogenic and tumor 
suppressor properties (Liss et al., 2010). 
Somatic 
V258I in lung cancer cell lines (Woo et al., 2002). 





The basic leucine zipper (basic motif + leucine zipper, 
JUNB dimerizes with either ATF2 or FOS to increased 
CBFB promoter activity, and further expression of 
MMP13, which suggests important role in 
neovascularization (Licht et al., 2006). 
Epithelial mesenchymal transition 
Note 
Epithelial mesenchymal transition (EMT) is 
characterized by the loss of the epithelial cell properties 
and the development of mesenchymal properties of 
cells, with altered cytoskeletal organization and 
enhanced migratory and invasive potentials.  
EMT is seen in embryonic development, 
organogenesis, wound healing, and oncogenesis. TGF-
beta induces EMT, and is up-regulated by ATF2 (Bakin 
et al., 2002; Venkov et al., 2011; Xu et al., 2012). 
Allergic asthma 
Note 
In a mouse model of allergic asthma, Aspergillus 
fumigatus provokes the secretion TNF (TNFalpha) by 
A. fumigatus-activated macrophages. In response to 
TNF, ATF2/JUN, RELA/RELA (p65/p65) and 
USF1/USF2 complexes are recruited to the PLA2G4C 
enhancer in lung epithelial cells (Bickford et al.,2012). 
Autoimmune diseases 
Note 
SMAD3 and ATF2 are activated during Theiler's virus 
(TMEV) infection (which may provoke an autoimmune 
demyelinating disease).  
SMAD3 and ATF2 activate IL-23 p19 promoter (Al-
Salleeh and Petro, 2008).  
IL-23 consists of a p40 subunit IL12B coupled to the
p19 subunit IL23A, and has an essential role in the 




CD39 is a transmembrane protein expressed on the 
surface of vascular and immune cells. CD39 inhibits 
platelet activation, maintains vascular fluidity, and 
provides protection from both cardiac and cerebral 
ischemia and reperfusion injuries. cAMP regulates 
CD39 expression through ATF2, which binds a CRE-
like regulatory element lying 210 bp upstream of the
CD39 transcriptional start point (Liao et al., 2010). 
Bone development 
Note 
ATF2 promotes chondrocyte proliferation and cartilage 
development through CCND1 upregulation in 
chondrocytes (Beier et al., 1999); mice carrying a 
germline mutation in ATF2 have a defect in 
endochondral ossification (Reimold et al., 1996).  
ATF2 regulates the expression of RB1, which regulates 
the G1- to S-phase transition by sequestering the E2F 
family members, necessary for cell cycle progression. 
When E2Fs are released, the cell is committed to  
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Table 1. Induction of activating transcription factors in the nucleus accumbens and their regulation of emotional behavior. (from Green et 
al., 2008). 
progress through the cell cycle, which is essential in 
regulating cell proliferation vs differentiation.of 
chondrocytes and endochondral bone growth (Vale-
Cruz et al., 2008).  
ATF2/CREB1 binds to CRE domain of TNFSF11 
(RANKL) promoter and TNFSF11 expression 
stimulates osteoclastogenesis in mouse 
stromal/osteoblast cells (Bai et al., 2005).  
Binding of JUN CREB1, ATF1, and ATF2 complexes 
are required for COL24A1 transcription, a marker of 
late osteoblast differentiation (Matsuo et al., 2006).  
Luteolin, a flavonoid, inhibits TNFSF11-induced 
osteoclastogenesis through the inhibition of ATF2 
phosphorylation (Lee et al., 2009). 
Brain 
Note 
ATF2 is expressed with large variations in intensity 
(and often highly expressed), according to the brain 
region examined. 
Altogether, ATF2 seems to play a fundamental role in 
neuronal viability and in neurological functions in the 
normal brain and is down-regulated in the hippocampus 
and the caudate nucleus in Alzheimer, Parkinson and 
Huntington diseases (Pearson et al., 2005). 
Mice carrying a germline mutation in ATF2 had a 
reduced number of cerebellar Purkinje cells, atrophic 
vestibular sense organs, an ataxic gait, 
hyperactivity,and decreased hearing (Reimold et al., 
1996).  
A missense mutation in ATF2 in dogs has shown to 
provoke an autosomal recessive disease with short 
stature and weakness at birth, ataxia and generalizd 
seizures, dysplastic foci consisting of clusters of 
intermixed granule and Purkinje cells, and death before 
7 weeks of age (Chen et al., 2008d). 
ATF2 plays critical roles for the expression of theTH 
gene (tyrosine hydroxylase) and for neurite extension 
of catecholaminergic neurons (Kojima et al., 2008). 
Neuronal-specific ATF2 expression is required for 
embryonic survival, ATF2 has a strong pro-survival 
role in somatic motoneurons of the brainstem, and loss
of functional ATF2 leads to hyperphosphorylated JNK 
and p38, and results in somatic and visceral 
motoneuron degeneration (Ackermann et al., 2011). 
On the other hand, activated ATF2 promotes apoptosis 
of various brain cells, of which are cerebellar granule 
neurons (Ramiro-Cortés et al., 2011; Song et al., 2011). 
ATF2/JUN heterodimers bind and activate CASP3, a 
key executor of neuronal apoptosis, in cerebellar 
granule neurons (Song et al., 2011). 
ATF2/JUN heterodimers bind and activate HRK (DP5, 
death protein 5/harakiri), a proapoptotic gene, 
promoting the death of sympathetic neurons (Ma et al., 
2007; Towers et al., 2009), but also ATF2/JUN binds to 
two conserved CRE sites in the DUSP1 (MKP1) 
promoter; overexpression of DUSP1 inhibits JNK-
mediated phosphorylation of JUN and protect 
sympathetic neurons from apoptosis (Kristiansen et al., 
2010). 
ATF2 overexpression in nucleus accumbens produces 
increases in emotional reactivity and antidepressant-
like responses (Green et al., 2008), see Table 1. 
Skin and skin cancers 
Note 
Inhibition of ATF2 with increased JNK/JUN and 
JUND induces apoptosis of melanoma cells (Bhoumik 
et al., 2004). MITF downregulation is mediated by 
ATF2/JUNB-dependent suppression of SOX10 
transcription (Shah et al., 2010); MITF is a 
transcription factor for tyrosinase (TYR) and plays a 
role in melanocyte development. 
ATF2 attenuates melanoma susceptibility to apoptosis. 
ATF2 control of melanoma development is mediated 
through its negative regulation of SOX10 and 
consequently of MITF transcription. The ratio of 
nuclear ATF2 to MITF expression is associated with 
poor prognosis (Shah et al., 2010). Assignment to the 
low-risk group in stage II melanoma requires elevatd 
levels of overall CTNNB1 (beta-catenin) and nuclear 
CDKN1A (p21WAF1), decreased levels of fibronectin, 
and distributions that favor nuclear concentration f r 
CDKN2A (p16INK4A) but cytoplasmic concentration 
for ATF2 (Gould Rothberg et al., 2009). 
Phosphorylated ATF2 (p-ATF2) is significantly 
overexpressed in cutaneous angiosarcoma (malignant 
tumor) and pyogenic granuloma (benign tumor) than in 
normal dermal vessels (Chen et al., 2008a); p-ATF2 is 
also overexpressed in cutaneous squamous cell 
carcinoma, Bowen's disease, and basal cell carcinomas, 
as compared to its expression in normal skin (Chen et 
al., 2008b).  
p-ATF2 is also overexpressed in eccrine porocarcinoma 
and eccrine poroma (Chen et al., 2008c). 
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ATF2 mutant mice in which the ATM phosphoacceptor 
sites (S472/S480) were mutated (ATF2KI mice) are 
more sensitive to ionizing radiation IR, exhibit 
increased intestinal cell apoptosis, develop a higher 
number of low-grade skin tumors (papillomas, 
squamous cell carcinomas, spindle cell carcinomas) (Li 
et al., 2010). A decrease of nuclear ATF2 and high 
CTNNB1 (beta-catenin) expression is seen in 
squamous cell carcinoma and basal cell carcinoma, 
compared to normal skin, while the cytoplasmic ATF2 
expression was not significantly different in cancer and 
normal skin (Bhoumik et al., 2008b). 
A nuclear localization of ATF2 would be associated 
with its oncogenic properties, and a cytosolic 
localization with its tumor suppressor properties (Lau 
and Ronai, 2012). 
High levels of ATF2/JUN dimers induce autocrine 
growth and primary tumor formation of fibrosarcomas 
in the chicken (van Dam and Castellazzi, 2001). 
Soft tissue sarcomas 
Note 
In human and murine synovial sarcoma cells with  
t(X;18)(p11.2;q11.2) and a hybrid SS18-SSX, BCL2 
expression is increased, but other anti-apoptotic genes, 
including MCL1 and BCL2A1 are repressed via 
binding of ATF2 to the cAMP-responsive element 




ATF2 was found to upregulate Fas/FasL in a human 
chronic myeloid leukemia cell line (Chen et al., 2009). 
NFE2L2 (NRF2) is a transcription activator of the bZIP 
family which binds to antioxidant response elements 
(ARE) in the promoter regions of target genes in 
response to oxidative stress.  
NFE2L2 positively regulates the expression the AP-1 
family proteins ATF2, JUN and FOS. NFE2L2/ARE 
pathway plays an important role in the induction of 
differentiation of myeloid leukemia cells by 1alpha,25-
dihydroxyvitamin D3 (1,25D), a strong differentiation 
agent (Bobilev et al., 2011). A crosstalk between 
NFE2L2 and ATF2 has also been noted in prostate 
cancer cells (Nair et al., 2010). 
Breast cancer 
Note 
The loss of one copy of p53 in ATF2+/- mice led to 
mammary tumor development, which supports the 
notion that ATF2 and p53 independently activate 
SERPINB5 and GADD45 expression (Maekawa et al., 
2008).  
ATF2/JUN mediate increased BIM expression in 
response to MAPK14 (p38alpha) signaling in cells 
detached from the extracellular matrix, indicating a 
contributing role for ATF2 in regulating acinar lumen 
formation, crucial for the development of mammary 
gland development, a function that may be crucial to its 
ability to suppress breast cancer. (Wen et al., 2011). 
ATF2/JUN binds to a potential CRE element of 
FOXP3, and induces its expression.  
FOXP3 acts as a transcriptional repressor of oncogenes 
such as ERBB2 and SKP2, and is able to cause 
apoptosis of breast cancer cells.  
The use of this ATF2-FOXP3 pathway may be of 
potential interest in future therapeutic approach of 
breast cancer. (Liu et al., 2009). 
Aggressive basal-like breast cancer cells exhibit high 
expression of FOSL1 (FRA1)/JUN dimers rather than 
ATF2/JUN dimers (Baan et al., 2010). 
Uterus cancer 
Note 
In PTEN-deficient endometrial cancers (which 
represent 1/3 to 3/4 of endometrial cancers), ATF2 is 
activated, while ATF2 shows a reduced expression in 
PTEN-positive endometrial cancers (Xiao et al., 2010). 
Prostate cancer 
Note 
Heparan-sulfate proteoglycans are required for 
maximal growth factor signaling in prostate cancer 
progression. HS2ST1 (heparan sulfate 2-O-
sulfotransferase, 2OST) is essential for maximal 
proliferation and invasion. HS2ST1 is upregulated by 
ATF2 (Ferguson and Datta, 2011). 
Lung cancer 
Note 
Patients with lung cancer showing high ANGPTL2 
expression in cancer cells had a poor prognosis. 
ANGPTL2 increases tumor angiogenesis, enhances 
tumor cell motility and invasion in an 
autocrine/paracrine manner, conferring an aggressiv 
metastatic tumor phenotype. NFATc (NFATC1 to 
NFATC4 and NFAT5) function in tumor cell 
development and metastasis. It has been found that 
NFATc form a complex with ATF2/JUN heterodimers 
that bind to the CRE site of ANGPTL2 and enhances 
ANGPTL2 expression (Endo et al., 2012). 
Other cancers 
Note 
Increased expression of ATF2 and ATF1 in 
nasopharyngeal carcinoma cells was associated with 
clinical stages (Su et al., 2011). 
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